Last reviewed · How we verify
Emineurina (CLOMETHIAZOLE)
Emineurina works by enhancing the activity of the neurotransmitter GABA, which helps to calm excessive brain activity.
Emineurina (Clomethiazole) is a small molecule drug that targets the GABA-A receptor alpha-1/beta-3/gamma-2 subunit, classified as a clomethiazole. It is used to treat alcohol withdrawal syndrome and insomnia. The commercial status of Emineurina is unknown, and it is not FDA-approved. Key safety considerations include its short half-life of 4.5 hours and moderate bioavailability of 25%. Further research is needed to determine its patent status and generic availability.
At a glance
| Generic name | CLOMETHIAZOLE |
|---|---|
| Drug class | clomethiazole |
| Target | GABA-A receptor alpha-1/beta-3/gamma-2 |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | discontinued |
Mechanism of action
Imagine your brain is like a busy city with many cars racing around. GABA is like a traffic cop that helps slow down the traffic. Emineurina helps the traffic cop work more effectively, reducing the noise and chaos in the brain.
Approved indications
- Alcohol withdrawal syndrome
- Insomnia
Common side effects
- Drug interaction
- Drug withdrawal convulsions
- Depressed level of consciousness
- Vascular encephalopathy
- Joint hyperextension
- Cogwheel rigidity
- Persecutory delusion
- Subileus
- Toxic epidermal necrolysis
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Emineurina CI brief — competitive landscape report
- Emineurina updates RSS · CI watch RSS